Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

January 19, 2024

https://www.globenewswire.com/news-release/2023/12/11/2793712/0/en/Orchard-Therapeutics-Receives-Swissmedic-Approval-for-Libmeldy-in-Early-onset-MLD.html

BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq:ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).

Read more at globenewswire.com

Related news for (ORTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.